Opening Doors for ending COVID-19 with Ivermectin

  • Opening Doors for ending COVID-19 with Ivermectin

  • Avatar

    IveyTech

    Member
    April 19, 2021 at 1:16 pm

    <div>

    The study analyzed 7 Randomized Controlled Trials (RCTs) and found that use of ivermectin reduces risk of death from Covid-19 by 81% as compared to controls.

    content://com.brave.browser_beta.FileProvider/images/screenshot/16188597046721045941310.jpg

    Each study on its own, and the set of studies combined, found that ivermectin was effective against Covid-19.

    “A total of 1323 patients were randomized in 7 RCTs per-formed in 6 countries. Four trials were multicentric. Iver-mectin treatment resulted in a lower mortality when compared to placebo: 14/703 (2%) vs 57/620 (9%),P<0.01, odds ratio 0.19 (0.10, 0.34).”

    The p-value for the meta-analysis was less than 0.01, which is clearly statistically significant. And the odds ratio means that Ivermectin reduced mortality by 81%, reducing risk of death from 1.00 for controls to 19% by comparison.

    RCTs are the so-called gold standard for studies, and this is a meta-analysis which combines several RCTs. These results are far better than any set of studies on Remdesivir, an approved and widely used (to the tune of 3 billion dollars) medication. And yet ivermectin is still rejected by medical authorities and government, costing untold suffering and a massive death toll, most of which could be avoided by prompt use of ivermectin and use of Vitamin D as a prophylaxis and an adjunct treatment.

    Ronald L Conte Jr
    covid.us.org

    </div><div>

    New Study of Ivermectin: Reduces Risk of Death

    </div><div>

    https://www.signavitae.com/articles/10.22514/sv.2021.043

    </div>

  • Avatar

    IveyTech

    Member
    April 19, 2021 at 1:43 pm
  • Avatar

    IveyTech

    Member
    April 20, 2021 at 1:21 pm

    A link to help discover more efforts to control this pandemic.

    At Covid US

    New Study of Ivermectin: Reduces Risk of Death

  • Avatar

    IveyTech

    Member
    April 20, 2021 at 1:23 pm

    YouTube Channels on Covid: Dr. Paul Marik | Dr. Mobeen Syed

  • Avatar

    IveyTech

    Member
    May 3, 2021 at 8:57 pm

    <div>
    </div><div>

    </div><div>

    Here are some of the characteristic effects that can be expected with Ivermectin use:

    </div><div>

    Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in Healthcare Workers

    “Ivermectin has 19 hours plasmatic half-life; an enterohepatic cycle and its active metabolites can remain in the blood for up to 72 hours. Its excretion is 99% hepatic and only 1% is excreted in the urine. If we give successive doses of Ivermectin on days 1, 4 and 7, the drug accumulation in blood is minimal (2, 3). Ivermectin is very lipophilic and its concentration in some tissues are high; active levels in the lungs reach almost 3 times higher than in the blood and is detectable in fat tissue for at least 7 days (4).

    Kaplan-Meier risk analysis showed that the prevention with Ivermectin occurred after the second dose was received on day 8. This finding could suggest that to achieve a preventive dose of Ivermectin in the tissues, a second dose is needed…”

    https://www.medrxiv.org/content/10.1101/2021.04.10.21255248v3.full-text

    “…713 participants were chosen, 326 in the Ivermectin group and 387 in the control group were considered for the preliminary analysis of this study. After the matching process with the Propensity Score, there were 271 members in each group for analysis

    The 51.5% of the participants in the Ivermectin group took 4 doses; 40.4% took 3 doses; 6.7% took 2 doses; 1.4% of the participants managed to take a single dose and then reported a positive COVID-19 infection.

    There were no severe side effects reported from the use of Ivermectin. Only minor side effects such as dizziness (3.7%), headache (1.5%), stomachache (1.4%), pruritus (1.1%), nausea (1.1%) and diarrhea (0.7%)…”

    </div>

  • Avatar

    IveyTech

    Member
    May 3, 2021 at 8:59 pm

    <div>
    </div><div>

    </div><div>

    Here are some of the characteristic effects that can be expected with Ivermectin use:

    </div><div>

    Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in Healthcare Workers

    “Ivermectin has 19 hours plasmatic half-life; an enterohepatic cycle and its active metabolites can remain in the blood for up to 72 hours. Its excretion is 99% hepatic and only 1% is excreted in the urine. If we give successive doses of Ivermectin on days 1, 4 and 7, the drug accumulation in blood is minimal (2, 3). Ivermectin is very lipophilic and its concentration in some tissues are high; active levels in the lungs reach almost 3 times higher than in the blood and is detectable in fat tissue for at least 7 days (4).

    Kaplan-Meier risk analysis showed that the prevention with Ivermectin occurred after the second dose was received on day 8. This finding could suggest that to achieve a preventive dose of Ivermectin in the tissues, a second dose is needed…”

    https://www.medrxiv.org/content/10.1101/2021.04.10.21255248v3.full-text

    “…713 participants were chosen, 326 in the Ivermectin group and 387 in the control group were considered for the preliminary analysis of this study. After the matching process with the Propensity Score, there were 271 members in each group for analysis

    The 51.5% of the participants in the Ivermectin group took 4 doses; 40.4% took 3 doses; 6.7% took 2 doses; 1.4% of the participants managed to take a single dose and then reported a positive COVID-19 infection.

    There were no severe side effects reported from the use of Ivermectin. Only minor side effects such as dizziness (3.7%), headache (1.5%), stomachache (1.4%), pruritus (1.1%), nausea (1.1%) and diarrhea (0.7%)…”

    This
    article is a preprint and has not been peer-reviewed [what does this
    mean?]. It reports new medical research that has yet to be evaluated and
    so should not be used to guide clinical practice.

    </div>

    • Avatar

      apptest

      Member
      May 4, 2021 at 12:20 pm

      Please disregard this post. please disregard this post

      • Avatar

        apptest

        Member
        May 4, 2021 at 12:21 pm

        <div><b>please disregard this post</div></b>

Log in to reply.

Original Post
0 of 0 posts June 2018
Now